Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (451-460 of 527) with videos related to

Pageof 53
Sort By:
Journal of Hepatology|November 7, 2022
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT studyMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adultsKevin L Russell, Richard E Rupp, Javier O Morales-Ramirez, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2018
A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinomaColin M Court, Shuang Hou, Paul Winograd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaRichard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studiesRichard S Finn, Kangsheng Gu, Xi Chen, et al.
The Lancet. Oncology|May 30, 2021
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialPeter R Galle, Richard S Finn, Shukui Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.
The American Journal of Surgical Pathology|October 25, 2016
Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter StudyPierre Russo, John C Magee, Robert A Anders, et al.
Pageof 53

Showing results (451-460 of 527) with videos related to

Sort By:
Pageof 53
Journal of Hepatology|November 7, 2022
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT studyMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adultsKevin L Russell, Richard E Rupp, Javier O Morales-Ramirez, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2018
A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinomaColin M Court, Shuang Hou, Paul Winograd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaRichard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studiesRichard S Finn, Kangsheng Gu, Xi Chen, et al.
The Lancet. Oncology|May 30, 2021
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialPeter R Galle, Richard S Finn, Shukui Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.
The American Journal of Surgical Pathology|October 25, 2016
Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter StudyPierre Russo, John C Magee, Robert A Anders, et al.
Pageof 53